Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AH-008 SAD Study in Healthy Subjects
NCT07697560Phase 1Completed
- Sponsor
- AnHorn Medicines
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing AH-008 with Matching placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 48 hours, Incidence of Clinically Significant Vital Sign Abnormalities at 48 hours and 9 more. Started Jun 2026; status: completed.
02
Drugs
acetyl hexapeptide-8
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07697560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697560.